Browse the evidence

Semaglutide oral is effective for weight loss compared to placebo, but is less effective than subcutaneous semaglutide formulations.

If you prefer oral medication, oral semaglutide is effective for weight loss compared to placebo. However, it is significantly less effective than the injectable form of semaglutide. If maximum weight loss is your primary goal, the injectable form is superior.

Extending the dosing interval of GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) from once-weekly to once-every-two-weeks reduces medication costs by approximately 50% while maintaining 70-75% of the weight loss efficacy.

If you are on a GLP-1 medication like semaglutide or tirzepatide and cost is a major barrier, discuss with your doctor the possibility of extending your dosing interval (e.g., from once a week to once every two weeks). While you might not lose as much weight as the maximum possible, you will likely retain most of the benefit (around 75%) while cutting your medication costs in half. This is particularly useful for ensuring long-term access to the medication.

Adhering to a low carbohydrate diet (approx. 30g/day) allows type 2 diabetes patients on insulin therapy to significantly reduce or completely stop insulin usage, while improving HbA1c and reducing body weight.

If you have Type 2 Diabetes and take insulin, discuss with your doctor a plan to drastically reduce carbohydrates to about 30 grams per day. This approach may allow you to lower or stop your insulin injections, lose weight, and improve your blood sugar control, provided you are monitored closely during the transition.

Semaglutide administration (0.5-1 mg weekly) enables obese end-stage renal disease (ESRD) patients on hemodialysis to achieve target BMI and become eligible for renal transplantation with substantial weight loss (11.7-14.8%) and minimal side effects.

If you have end-stage kidney disease and are on dialysis, obesity might currently block you from getting a transplant. This case series suggests that using semaglutide (a weekly injection) can help you lose enough weight (around 12-15% of body weight) to meet transplant criteria. It was well-tolerated in these patients, but requires close monitoring by your nephrologist to adjust dialysis settings as you lose weight. It serves as a bridge to surgery when lifestyle changes or bariatric surgery are not options.

GLP-1 analogues (liraglutide and semaglutide) enable significant weight loss (approx. 14%) in obese patients with end-stage lung disease, thereby bridging the gap to lung transplantation eligibility when dietary and exercise interventions fail.

If you have severe lung disease and a BMI that bars you from transplant, ask your care team about GLP-1 medications (like semaglutide or liraglutide). This case shows they can help you lose enough weight to qualify for surgery when diet and exercise aren't enough, even while taking steroids.

Extending the dosing interval of GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) from once-weekly to once-every-two-weeks maintains approximately 70-75% of the weight loss efficacy while reducing total drug cost by 50%.

If you are taking a GLP-1 drug like semaglutide or tirzepatide, ask your doctor about extending your dosing interval to every two weeks. Mathematical models suggest this could cut your medication costs by 50% while keeping about 75% of the weight loss benefits. This is not a substitute for medical advice, but it is a potential strategy to improve affordability and adherence.

For patients on lower doses of tirzepatide (e.g., 5 mg), switching to a less frequent dosing schedule (e.g., every two weeks) while simultaneously increasing the dose size (e.g., to 10 mg or 15 mg) can maintain or even exceed the weight loss efficacy of the standard once-weekly regimen.

If you are on a lower dose of tirzepatide (5 mg) and find it expensive, ask your doctor if switching to a higher dose (10 mg or 15 mg) taken every two weeks is an option. This strategy might keep your weight loss results the same or even better while cutting your costs in half. However, be aware that higher doses may increase side effects, so this requires careful medical supervision.

GLP-1 receptor agonists have assumed the primary role in treating obesity with significant weight loss.

Practitioners should consider GLP-1 receptor agonists as a treatment for obesity.

Weekly subcutaneous administration of GLP-1 receptor agonist (dulaglutide) significantly reduces HbA1c and body weight in patients with Type 2 Diabetes Mellitus who fail to adhere to low carbohydrate diet (LCD) or calorie restriction diet (CRD).

If you have Type 2 Diabetes and struggle to maintain a low-carb or calorie-restricted diet due to lifestyle, cognitive issues, or lack of support, ask your doctor about once-weekly GLP-1 receptor agonists like dulaglutide. This medication can significantly lower blood sugar (HbA1c) and help with weight loss even when dietary adherence is inconsistent. It is particularly useful for elderly patients or those with comorbidities who find daily management difficult.

Intermittent Energy Restriction (IER) involving alternating periods of energy restriction with refeeds may preserve resting energy expenditure (REE) and fat-free mass (FFM) better than Continuous Energy Restriction (CER) during weight loss, though evidence in athletes is currently limited.

If you are an athlete struggling with plateaus or extreme hunger on a standard diet, try adding 'refeed' days where you eat at maintenance or slightly above. This might help preserve your muscle and keep your metabolism from slowing down as much as it would on a constant low-calorie diet. However, be aware that direct proof in athletes is still scarce, so monitor your progress closely.

Combination anti-obesity medication regimens including GLP-1 receptor agonists can achieve total body weight loss (approx. 32.5%) comparable to metabolic/bariatric surgery in patients with severe obesity.

If you have severe obesity and have not lost significant weight with standard medications or lifestyle changes alone, ask your doctor about combination therapy. Adding a GLP-1 agonist (like semaglutide) to other approved weight-loss drugs may produce results similar to bariatric surgery. This approach targets multiple biological pathways (hunger, satiety, metabolism) simultaneously, which may be necessary for severe cases.

The effect of lifestyle intervention on cognitive impairment varies by baseline BMI, with potential benefit for overweight individuals (BMI 25-29) and potential harm for obese individuals (BMI ≥40).

For overweight individuals (BMI 25-29) with type 2 diabetes, lifestyle intervention may offer some cognitive protection. However, for those with severe obesity (BMI ≥40), the same intervention might be associated with a higher risk of cognitive impairment compared to controls. This suggests that the cognitive impact of weight loss may depend on starting weight, with potential benefits for the overweight and potential risks for the severely obese, possibly due to the loss of neuroprotective factors associated with higher body fat.

Medium-term resistance exercise training (7-23 weeks) significantly reduces fasted insulin and insulin resistance (HOMA-IR) in adults, whereas short-term and long-term effects are less consistent or non-significant.

If your goal is to improve insulin sensitivity, aim for 7-23 weeks of consistent resistance training (2-3 times per week). This duration window appears optimal for reducing fasting insulin and HOMA-IR scores.

Muscle-derived musclin (encoded by Ostn) is required for full endurance training adaptation, as its absence impairs training-induced improvements in running performance and mitochondrial activity.

Current evidence for musclin's role in training adaptation comes from short-term mouse studies. While it appears important for performance gains in mice, there is no human data yet. Do not seek out musclin-based interventions for training enhancement until human trials are available.

Traditional Chinese Medicine (TCM) interventions, including acupuncture, herbal medicine, and dietary therapy, may help manage obesity and diabetes by regulating gut microbiota, reducing inflammation, and improving insulin sensitivity.

If you are managing obesity or diabetes, TCM modalities like acupuncture, specific herbal formulas (e.g., Ginseng, Cinnamon), and dietary adjustments may offer supportive benefits by improving insulin sensitivity and gut health. However, these should not replace standard lifestyle changes or prescribed medications without consulting your doctor, as the evidence is still evolving.

Soy protein supplementation has an inconsistent effect on testosterone and cortisol levels, and more research is required to determine its impact on anabolic hormones.

Don't worry about soy protein affecting your hormones. The research shows inconsistent effects on testosterone and cortisol, with no clear evidence of negative impacts. You can consume soy protein without fear of hormonal disruption.

Newer GLP-1/GIP receptor agonists (semaglutide, tirzepatide) are expected to provide superior post-operative weight loss compared to prior GLP-1 RAs, despite a lack of specific post-surgical clinical trials.

Semaglutide and tirzepatide show impressive weight loss in non-surgical patients, but there is currently no data on their effectiveness specifically after bariatric surgery. Liraglutide and topiramate remain the best-supported options for post-surgical weight regain.

Off-label use of topiramate and/or metformin achieves clinically significant preoperative weight loss (>8% total body weight loss) in patients with BMI ≥50 kg/m2 who fail standard bariatric nutritional prescriptions due to dysregulated appetite.

If you have a BMI over 50 and are waiting for bariatric surgery but struggle with hunger and cravings despite dieting, ask your doctor about off-label use of generic Topiramate or Metformin. These drugs can help suppress appetite and facilitate the weight loss needed to make surgery safer and more successful, often at a fraction of the cost of newer branded drugs.

GLP-1 receptor agonists and GIP may influence cardiac lipid metabolism by modulating LPL activity, potentially offering cardioprotection, though the specific effect on cardiac LPL remains unclear.

GLP-1 and GIP drugs help with weight and glucose, but they may also directly affect how the heart processes fat. The exact impact on the heart is still being studied, but it may offer additional protection beyond weight loss.

Semaglutide treatment (up to 2.4 mg weekly) significantly reduces body weight, fat mass, and emotional eating behaviors in patients with hypothalamic obesity resulting from craniopharyngioma.

For patients with hypothalamic obesity due to brain tumors or surgery, semaglutide (up to 2.4 mg/week) combined with dietary counseling can significantly reduce weight and emotional eating, even when other treatments fail. It works by targeting brain circuits beyond the damaged hypothalamus.

Tirzepatide use in non-diabetic obese patients can induce severe ketoacidosis, primarily through starvation ketosis driven by gastrointestinal side effects and reduced caloric intake, rather than diabetic mechanisms.

If you are using tirzepatide for weight loss, do not buy it over the counter without medical oversight. Be aware that severe nausea, vomiting, or diarrhea combined with low food intake can lead to dangerous acid buildup (ketoacidosis), even if you do not have diabetes. Seek immediate medical attention if you experience abdominal pain, vomiting, and rapid breathing.

Tirzepatide use is associated with a risk of idiosyncratic acute liver injury, characterized by severe hepatotoxicity and coagulopathy, which resolves upon discontinuation of the drug.

If you are using tirzepatide for weight loss, do not skip liver function tests. While liver injury is rare, it can be severe and rapid. Report any persistent abdominal pain, vomiting, or yellowing of skin/eyes immediately. The drug should be stopped if liver enzymes rise significantly.

GLP1:GIP:Gcg triple agonists (SAR441255) show potential for weight loss and neurological benefits, including improved memory in mouse models of TBI and Alzheimer's disease.

GLP1:GIP:Gcg triple agonists like SAR441255 show potential for weight loss and neurological benefits, including improved memory in animal models of TBI and Alzheimer's disease. However, human data is preliminary, and glycemic benefits may be inferior to dual agonists. These therapies are in early development.

Tirzepatide use is associated with a probable risk of severe rhabdomyolysis and necrotising myopathy, potentially mediated by GLP-1 receptor effects on skeletal muscle glucose metabolism.

If you are taking tirzepatide (or similar GLP-1 drugs) and experience sudden, severe muscle pain, swelling, or weakness—especially if it doesn't match your activity level—seek medical attention immediately. Ask for a Creatine Kinase (CK) blood test. Stopping the medication and receiving IV fluids can resolve the condition, as seen in this case.